Ireland
--:--IST
Latest
PulseAI of Belfast Says FDA Cleared Its Wearable ECG AI Airmid Éireann 1.6 Adds India and China Trials, Swiss Prices Irish Cancer Trial Enrolment at 2.9%, Under Half 6% Target FDA Accelerated Approval for J&J's Head and Neck Cancer Drug Korea Misses 2026 Biosimilar Approvals, Bets on Keytruda ArrayPatch Closes €3.2m Seed for GLP-1 Microneedle Patch PulseAI of Belfast Says FDA Cleared Its Wearable ECG AI Airmid Éireann 1.6 Adds India and China Trials, Swiss Prices Irish Cancer Trial Enrolment at 2.9%, Under Half 6% Target FDA Accelerated Approval for J&J's Head and Neck Cancer Drug Korea Misses 2026 Biosimilar Approvals, Bets on Keytruda ArrayPatch Closes €3.2m Seed for GLP-1 Microneedle Patch
Clinical Trials in China / NCT06700616
Active, not recruiting Observational

A Study in Patients With Myasthenia Gravis in China

NCT06700616 · tracked via the Priya Life Science China tracker
Sponsor
AstraZeneca
Phase
Observational
Started
2024-09-26
Last updated
2026-09-18

Condition(s) studied

Myasthenia Gravis

Study summary

This study is a multi-center, prospective cohort study designed to characterize current clinical practice, clinical and patient-reported outcomes (PROs), disease prognosis, treatment patterns and healthcare resource utilization for Chinese patients with myasthenia gravis (MG). This study will enroll patients with MG as diagnosed by physician. Approximately 1,200 MG patients are intended to be recruited from approximately 40 sites across majority of regions in China. The clinical and PROs included MGFA class, MGFA PIS, MG-ADL (Activities of Daily Living), QMG (Quantitative MG score), MG QOL-15R, EQ-5D etc. All MG patients enrolled will be followed up every 6 months until end of 2027.

Eligibility

Sex
ALL
Min age
0 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: This study will enroll patients of all ages who are diagnosed with MG of all MGFA classifications by physicians. 1. Patients must have the following data to be enrolled in this study: * MGFA classification * MG-ADL score 2. MG patients or their legal guardians/representatives are able to sign the Informed Consent Form (ICF). Exclusion Criteria: 1. Patients aged ≥18 years with ocular myasthenia gravis (MGFA class I) lasting for more than 2 years; 2. Patients who are currently participating in an interventional clinical trial cannot be enrolled in this study.

Primary outcome measure(s)

  • Clinical outcome — Every 6 months up to 3 years
    MGFA classification (e.g I, II, III, IV, V)
  • Treatment method — Every 6 months up to 3 years
    Targeted treatment methods (list of methods, including medication, immunoglobulin, plasma exchange, surgery etc. )
  • Patient-reported outcome — Every 6 months up to 3 years
    MG-Activities of Daily Living (MG-ADL, aggregated value in a scale, ranged 0- best to 24- worst)
  • Clinical outcome — Every 6 months up to 3 years
    MGFA Post-intervention Status (e.g. CSR, PR, MM)
  • Clinical outcome — Every 6 months up to 3 years
    Quantitative MG score (QMG, aggregated value in a scale, ranged 0- best to 39-worst)
  • Clinical outcome — Every 6 months up to 3 years
    Physician-reported MG crisis
  • Clinical outcome — Every 6 months up to 3 years
    Death
  • Patient-reported outcome — Every 6 months up to 3 years
    MG-Quality of Life 15-Revised (MG-QoL15-r, aggregated value in a scale for quality of life, ranged 0- best to 60- worst)
  • Patient-reported outcome — Every 6 months up to 3 years
    EuroQol-5D (separate value for five dimensions in a scale for quality of life)
  • Treatment duration — Every 6 months up to 3 years
    Therapies start and end date
  • Treatment dose — Every 6 months up to 3 years
    Dose (e.g. mg)
  • Treatment frequency — Every 6 months up to 3 years
    Frequency (e.g. times/day)

Trial sites (20)

FacilityCityRegionStatus
Research Site Beijing China
Research Site Chengdu China
Research Site Fuzhou China
Research Site Guangzhou China
Research Site Guiyang China
Research Site Harbin China
Research Site Hebei China
Research Site Henan China
Research Site Inner Mongolia China
Research Site Jiangsu China
Research Site Lanzhou China
Research Site Nanning China
Research Site Qingdao China
Research Site Taiyuan China
Research Site Tianjin China
Research Site Ürümqi China
Research Site Wenzhou China
Research Site Wuhan China
Research Site Xi'an China
Research Site Yinchuan China

More AstraZeneca trials in China

This is a Multi-centre, Multi-drug, Platform Study in Chinese Participants Living With Obesity / Overweight Active, not recruiting
Implementation of Standardized Early Identification and Diagnosis for Transthyretin Amyloidosis (ATTR) in High-Risk Populations Active, not recruiting
Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malignancies Active, not recruiting
Study for AZD4360 in Participants With Advanced Solid Tumours Active, not recruiting
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors Recruiting

Other trials for the same condition

Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/ BCMA（QT-019C） in Patients With r/ r Neurological Autoimmune Diseases Starting soon
Precision Diagnosis and Prospective Cohort Study for Myasthenia Gravis: Multicenter Analysis in China Recruiting
Safety and Efficacy of CD19-BCMA Targeted CAR-T Therapy for Refractory Generalized Myasthenia Gravis Recruiting
Cohort Study on Neuroimmune Diseases in the Reproductive Age Recruiting
Construction of A Multimodal Digital Assessment Model for Myasthenia Gravis Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06700616 on ClinicalTrials.gov ↗ ← All trials in China